PROs
We're sorry, but we're unable to process your login. Please try again.
We're sorry, you are not authorized to access this site. Please contact your local Merck representative if you have any inquiries.
This page requires you to register for an account with Merck. Please login with your Merck account credentials below, or register for a new account.

Log in with Merck
{* #signInForm *}
{* signInEmailAddress *}
{* currentPassword *}
{* captcha *}
{* /signInForm *}

Patient Reported Outcomes (PROs)

Use of PROs to improve diagnosis, treatment, and care of patients with MS.

Outcomes Study

This study is a multi-center observational real-world platform which aims to integrate data from multiple sources to facilitate patient and provider engagement, shared decision making, and participation in high-priority research questions, as well as identify a core set of patient reported outcomes (PROs) that correlates with disease progression and activity

Partner: Tornatore, MedStar Georgetown; English, MS Center of Atlanta

Status: Ongoing

Outcomes Study Description Outcomes Study Description
Outcomes Study Description
Outcomes Study Description
View
Outcomes Study Infographic Outcomes Study Infographic
Outcomes Study Infographic
Outcomes Study Infographic
View
Poster presented at AAN 2023 Poster presented at AAN 2023
Poster presented at AAN 2023
Poster presented at AAN 2023
View
Poster presented at ECTRIMS 2023 Poster presented at ECTRIMS 2023
Poster presented at ECTRIMS 2023
Poster presented at ECTRIMS 2023
View

Next Gen MS

This study will use PRO data collected in the MS-LINK Outcomes study in a feed-forward method to evaluate if PRO data can be practically utilized within real healthcare systems to improve quality of life or delay disability progression in adults living with MS

Partner: Oliver, Dartmouth

Status: Ongoing

Next Gen MS Study Description Next Gen MS Study Description
Next Gen MS Study Description
Next Gen MS Study Description
View
Poster presented at CMSC 2023 Poster presented at CMSC 2023
Poster presented at CMSC 2023
Poster presented at CMSC 2023
View
Poster presented at ECTRIMS 2023 Poster presented at ECTRIMS 2023
Poster presented at ECTRIMS 2023
Poster presented at ECTRIMS 2023
View

DISCOMS Extension

This study aims to provide data on the durability of disease inactivity, and potential risks, after discontinuing DMT(s) in MS

Partner: Cutter, University of Alabama; Corboy, University of Colorado

Status: Complete

DISCOMS Extension Study Description DISCOMS Extension Study Description
DISCOMS Extension Study Description
DISCOMS Extension Study Description
View
Poster presented at ECTRIMS 2023 Poster presented at ECTRIMS 2023
Poster presented at ECTRIMS 2023
Poster presented at ECTRIMS 2023
View

    

Site Exit Disclaimer

You are now leaving the website of EMD Serono, the biopharma business of Merck KGaA, Darmstadt, Germany. This link will either lead to a different website maintained by EMD Serono/its global business, or a different website/resource maintained by 3rd parties.

If you are visiting a 3rd party website, we have no control over the content and are not responsible for and make no representation as to the accuracy or any other aspect of such resource or the privacy practices of such 3rd party. Providing links to a 3rd party website does not constitute EMD Serono’s endorsement of such website or the information or products presented on such website. 

Welcome to MS-LINK Research

Help us direct you to the right information by selecting one of the following options:

I’m a Healthcare Professional

Please click below. 

 

I’m a patient or caregiver

Please click below.

YES, I’m a patient/caregiver